New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

Core Insights - Novartis announced new data on Kesimpta® (ofatumumab) for relapsing multiple sclerosis (RMS) to be presented at ECTRIMS 2025 Annual Meeting [1] - The studies demonstrate significant efficacy and safety of Kesimpta in patients who switched from other therapies [2][3] Study Findings - The ARTIOS Phase IIIb study showed a low annualized relapse rate (ARR) of 0.06 over 96 weeks for patients switching to Kesimpta, with over 90% achieving no evidence of disease activity (NEDA-3) [2][6] - The ALITHIOS study indicated that more than 90% of recently diagnosed treatment-naïve patients achieved NEDA-3 at seven years, highlighting long-term efficacy [3][6] Safety Profile - No new safety concerns were reported in both studies after switching to Kesimpta, reinforcing its favorable safety profile [2][3] Product Overview - Kesimpta is a targeted B-cell therapy administered via subcutaneous injection, approved in over 92 countries, with more than 150,000 patients treated as of August 2025 [5][6] Company Background - Novartis has over 80 years of experience in tackling neurological conditions and continues to develop transformative treatments in multiple sclerosis and other neurological diseases [7]